• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    American health & drug benefits

    American health & drug benefits

    JournalISSN 1942-2962eISSN 1942-2970中科院 医学 4区

    年发文量

    研究主题

    论文(946)

    排序
    1Trends in Utilization, Prices, and Spending for Oral Medications for Breast Cancer Treatment in the US Medicaid Population, 2008-2019
    Fatimah Hussain Alyami,Jeff Jianfei Guo

    BACKGROUND: Breast cancer is the second leading cause of death among women in the United States. The high cost of oral oncology drugs in breast cancer treatment impacts Medicaid budgets and potentially threatens access to therapies for patients and clinical outcomes. OBJECTIVE: To examine the trends in utilization, pharmacy reimbursement, and prices of oral breast cancer therapies in the US Medicaid-covered population from 2008 to 2019. METHODS: We conducted a retrospective drug utilization study. Pharmacy data and reimbursement of brand-name and generic oral therapies for breast cancer were extracted from the Centers for Medicare & Medicaid Services Medicaid state drug utilization data between 2008 and 2019. Those oral therapies included protein kinase inhibitors, aromatase inhibitors, pyrimidine analogs, and antiestrogens. For each brand-name and generic drug included in the study, we calculated the annual prescription counts and reimbursement amounts, and estimated the annual average drug price by calculating the average reimbursement per prescription. RESULTS: The annual generic drug use increased from 68,213 prescriptions in 2008 to 589,506 in 2019, whereas spending increased from $2.2 million in 2008 to $43 million in 2019. For brandname drugs, the number of prescriptions decreased by 59% from 143,009 in 2008 to 58,272 in 2019; however, spending increased significantly by 819%, from $72.5 million in 2008 to $666.3 million in 2019, in part as a result of recently marketed expensive therapies, such as protein kinase inhibitors. The cost per prescription as a drug price proxy for most brand-name drugs increased over the study period. For example, the cost of Afinitor increased by 219% from $5280 in 2009 to $16,868 in 2019. Nevertheless, the price per prescription for generic therapies declined over time as a result of patent expirations. CONCLUSIONS: A significant increase in Medicaid spending on oral breast cancer medications was observed during the 12-year study period with the increase in drug use, and a competition occurred between generic and brand-name oral breast cancer drugs in the Medicaid market. Our study highlights the importance of implementing cost-containment strategies, such as drug utilization review programs and mandatory generic drug substitution, to control the economic burden of breast cancer therapies on the Medicaid budget.

    2023
    引用
    AI阅读
    加入学术空间
    2Multiple Sclerosis: Systemic Challenges to Cost-Effective Care
    David R Weinstein,Gary M Owens, Ankit Gandhi

    Background Multiple sclerosis (MS) is a progressive autoimmune disorder of the central nervous system characterized by symptoms including reduced mobility, pain, fatigue, and spasticity. MS affects nearly 1 million people in the United States, with significant negative impact on a patient's quality of life, and an average lifetime cost of care in excess of $4 million. The cost-effective management of patients with MS faces several challenges. Objective To review the challenges to the cost-effective management of patients with MS, and to offer healthcare stakeholders a roadmap to address them. Discussion The cost-effective management of patients with MS, which is driven largely by how quickly a patient receives effective medication therapy, is challenged by a paucity of between-office-visit clinical data, variability of provider expertise with magnetic resonance imaging (MRI), MRI machine quality, lack of standards for MRI machines and reports, misaligned financial incentives, the limited number of available Current Procedural Terminology (CPT) codes for brain MRI, the complexity of disease-modifying therapy (DMT) selection, poor patient adherence to treatment plans, poor communication among providers, and a lack of objective measures of disease progression. Conclusion Insurers, neurologists, researchers, and patient advocacy groups must address the needs of patients with MS holistically. These efforts should include establishing standards for MRI machines and reports, matching patients with MS specialists, aligning financial incentives, including creating a new CPT code for complex brain MRI, streamlining prior authorization processes of DMTs, using technology to gather patient data and improve coordination of care, and developing better measurement tools of disease activity.

    2022引用:1
    引用
    AI阅读
    加入学术空间
    3Cost-Effectiveness of De Novo Simvastatin As Adjunctive Therapy in Patients Ill With
    Sara Mostafa Eladawy, Mohamed Abd Alsalam Elgendy,Mamdouh Ahmed Zaki,Naglaa Samir Bazan

    OBJECTIVE: To evaluate the cost-effectiveness of de novo simvastatin plus standard therapy versus standard therapy alone in patients with sepsis during a 1-year period.METHODS: A total of 145 critically ill patients were recruited in an open-label, randomized, con-trolled clinical trial. Of these, 80 patients received standard therapy according to Surviving Sepsis Campaign Guidelines 2012, and 65 received oral simvastatin plus standard therapy. The outcomes assessed include survival at the end of 1-year follow-up and intensive care unit (ICU) length of stay. Per protocol analysis was used.RESULTS: The ICU length of stay was significantly decreased in the simvastatin group (P = .001). At 1 year, 46% of patients in the simvastatin group survived compared with 35% in the standard therapy group, although this was not significant (P = .173). However, a Kaplan-Meier curve showed a significant difference that favored the standard arm (P = .01). Simvastatin was the dominant treatment option based on lower total direct costs versus the standard group. Savings related to ICU length of stay was the main determinant of the cost-saving results of simvastatin. Incremental cost-effectiveness ratio was negative and thus was not calculated. Probabilistic sensitivity and one-way sensitivity analyses were done, and results were robust to change.CONCLUSION: de novo simvastatin as an adjunct to standard therapy in ICU patients with sepsis lowered the overall cost by shortening ICU length of stay and its associated costs, but generaliza-tion to patients with different magnitudes of sepsis severity and to different ethnic groups requires further investigation.

    2022
    引用
    AI阅读
    加入学术空间
    4Implementation Strategies of Biosimilars in Healthcare Systems: the Path Forward
    Raymond K. Cross, Amy L. Stewart, Colin C. Edgerton,Bhavesh Shah,John A. Welz,Jonathan Kay

    BACKGROUND: Biosimilars, highly similar versions of biologic agents, can offer patients equivalent efficacy at reduced costs, which could help expand medication access to more patients. Market uptake and adoption of biosimilars in the United States have been relatively slow, however. This summary aims to explore the challenges and opportunities in healthcare systemwide adoption of biosimilars based on a roundtable discussion including multistakeholder healthcare providers. OBJECTIVES: To identify barriers that contribute to slow market uptake and adoption of biosimilars in the United States and suggest strategies to mitigate such barriers. DISCUSSION: The article systematically examines factors affecting biosimilar adoption and offers insights into potential solutions and system-based strategies to facilitate the adoption and implementation of biosimilar agents in healthcare systems. Misinformation and knowledge gaps among providers and patients continue to hinder the adoption of biosimilars. External barriers related to payers' incentives, patent litigation, and Medicare policy were also identified as obstacles to the adoption of biosimilars. Strategies can be designed and implemented to overcome many of these barriers and realize the economic and societal benefits of biosimilar drugs. CONCLUSION: Overcoming key barriers to biosimilar adoption may be possible by implementing actionable system-level strategies that enable the dissemination of accurate and timely information to key stakeholders and improve organizational readiness for institutions considering biosimilar implementation. The resulting benefits would help to achieve the goals of reducing cost and thereby improving patient access while simultaneously reducing the historical barriers to broad biosimilar adoption.

    2022引用:2
    引用
    AI阅读
    加入学术空间
    5The Quality of Care and Economic Burden of COPD in the United States: Considerations for Managing Patients and Improving Outcomes
    David L. Larsen,Hitesh Gandhi,Michael Pollack,Norbert Feigler,Sushma Patel,Robert A. Wise

    BACKGROUND: The economic and societal burdens of chronic obstructive pulmonary disease (COPD) in the United States are substantial and increasing. COPD had projected US costs of $49 billion in 2020, and chronic lower respiratory diseases, including COPD, were the fourth leading cause of death in the United States in 2019. COPD-related hospitalizations for exacerbations are the greatest driver of costs; however, numerous factors shape the current landscape of COPD, and thus multiple opportunities to improve quality of care for patients are being explored. OBJECTIVES: To describe the existing burden, unmet needs, and related economics of COPD in relation to quality of care and to discuss approaches to reduce the cost of managing COPD, including advancements in maintenance therapy. DISCUSSION: Comorbidities are associated with increased hospitalizations and costs, worse outcomes, and reduced quality of life in patients with COPD. The severity of COPD and the rate of exacerbations are important drivers of medical costs, which highlights the importance of early diagnosis, early recognition of exacerbations, and timely initiation of therapy. The reduction of COPD hospital readmissions is of critical importance to reduce costs, per the recommendations of organizations such as the Centers for Medicare & Medicaid Services. Performance measures offered by the Healthcare Effectiveness Data and Information Set are a helpful tool; however, objective data evaluating how improving the quality of COPD care translates to reduced costs to the healthcare system are lacking. CONCLUSION: A comprehensive strategy to reduce COPD mortality and clinical burden will require a multifaceted approach. Key methods include improved patient access to care; early intervention with appropriate, effective treatment, such as single-inhaler triple therapies; proactive adherence monitoring; early recognition of worsening COPD and modification of treatment; disease management strategies, including smoking cessation and pulmonary rehabilitation; and evidence-based metrics to evaluate hospital readmission programs.

    2022引用:5
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 946 篇论文

    高被引作者

    作者引用发文
    Lisa A Raedler110027
    David B Nash71471
    Buffery Dalia61725
    Quang T. Nguyen5377
    Loretta Fala53416
    Bruce Pyenson41111
    Fuhr Joseph P4094
    Erwin A. Blackstone4093
    Fitch Kathryn3868
    Vogenberg F Randy34929

    高产作者

    作者引用发文
    David B Nash71471
    Vogenberg F Randy34929
    Lisa A Raedler110027
    Buffery Dalia61725
    Jack E Fincham3921
    James T. Kenney9918
    Michael F. Murphy21516
    Loretta Fala53416
    Gary Branning16015
    Matthew Mitchell6315

    相关期刊

    Drugs - real world outcomes
    Journal of market access & health policy
    The Senior care pharmacist
    Farmacia Hospitalaria
    Journal of Managed Care Pharmacy
    U.S. Pharmacist
    Global & Regional Health Technology Assessment
    Farmeconomia. Health economics and therapeutic pathways
    Journal of managed care & specialty pharmacy
    Journal of Health Economics and Outcomes Research